Guardant Health's InfinityAI Aids ENHERTU Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy GH?
Guardant Health announced that real-world evidence generated from Guardant's InfinityAI contributed to the recent approval of ENHERTU, developed and commercialized by Daiichi Sankyo in Japan, for the treatment of patients with HER2-positive advanced or recurrent solid cancers refractory or intolerant to standard treatments. This approval, granted by Japan's Ministry of Health, Labour and Welfare, MHLW, was supported by data from the HERALD, DESTINY-PanTumor02, DESTINY-CRC02 and DESTINY-Lung01 clinical trials and supplemental real-world evidence, RWE, generated using the real-world data platform from InfinityAI, Guardant Health's artificial intelligence platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GH
Wall Street analysts forecast GH stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 86.200
Low
105.00
Averages
124.69
High
155.00
Current: 86.200
Low
105.00
Averages
124.69
High
155.00
About GH
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Verana Health Partners with Guardant Health to Enhance Cancer Therapy Development
- Data Integration Advantage: The partnership between Verana Health and Guardant Health combines high-quality EHR data with genomic data, enabling biopharmaceutical researchers to better understand the correlations between molecular biomarkers and clinical outcomes, thereby accelerating the development of new therapies and enhancing patient care quality.
- Enhanced Clinical Insights: By integrating NMIBC EHR data with genomic data, researchers can more accurately assess patient risk and optimize treatment choices, particularly regarding the applicability of BCG therapy, which improves treatment efficacy and patient satisfaction.
- Market Coverage Expansion: This collaboration extends Verana Health's cancer care data to solid tumors such as lung, breast, and colorectal cancers, enhancing the diversity of the dataset and clinical insights, allowing it to serve 17 of the top 20 global biopharma companies.
- Regulatory Collaboration Strengthening: The combined regulatory expertise of both companies positions them as a top-tier partner for close collaboration with the FDA, further solidifying Verana Health's standing in the biopharma industry and accelerating the implementation of clinical trial solutions.
See More
Verana Health Partners with Guardant Health to Enhance Oncology Research
- Data Integration Enhances Research Efficiency: The partnership between Verana Health and Guardant Health integrates high-quality EHR data with genomic data, enabling biopharmaceutical researchers to more rapidly understand the correlations between molecular biomarkers and clinical outcomes, thereby accelerating the development of new therapies.
- Enhanced Clinical Insights: By combining NMIBC EHR data with genomic data, researchers can better select treatment options and optimize decision-making for non-muscle invasive bladder cancer patients, ultimately improving patient treatment outcomes.
- Expanded Patient Coverage: This collaboration allows Verana Health to cover over 10 million oncology patients and establishes strong ties with 17 of the top 20 global biopharma companies, enhancing its influence within the biopharma industry.
- Regulatory Collaboration Advantage: The combined regulatory expertise of both companies positions them as a top-tier partner for FDA collaborations, further driving the acceleration of clinical trial solutions and improving R&D efficiency in the life sciences sector.
See More
Guardant Reveal Expands Cancer Detection Utility in MRD Monitoring
- Tumor Classification Advances: Guardant360 Tissue demonstrates a 92% accuracy rate in identifying the likely origin of unknown primary cancers from over 6,000 tissue samples, enhancing diagnostic precision and providing new avenues for complex cancer treatment.
- Liquid Biopsy Technology Enhancement: Guardant360 Liquid achieves an actionable finding rate of 85% in metastatic breast cancer patients and 89% in advanced colorectal cancer patients, indicating its potential in clinical applications to offer personalized treatment options for more patients.
- New Cancer Detection Capability: Guardant Reveal showcases its ability to identify new primary malignancies during MRD monitoring, utilizing non-invasive liquid biopsy technology to detect new cancers over time, significantly increasing the potential for early intervention.
- Precision Treatment Opportunities: Research indicates that the tissue-based genomic instability score (GIS) can accurately detect DNA repair deficiencies in breast, ovarian, and pancreatic cancers, providing patients with opportunities for PARP inhibitor treatments, further advancing the field of precision medicine.
See More
U.S.-Iran Conflict Triggers Volatility in Healthcare Stocks
- Oversold Condition: The ongoing U.S.-Iran conflict has led to oversold conditions in the healthcare sector, with Ionis Pharmaceuticals (IONS) experiencing a 12.27% decline over the past 15 days, indicating heightened market concerns.
- Key Stock Performance: Guardant Health (GH) and Dexcom (DXCM) fell by 8.96% and 12.52%, respectively, while Humana (HUM) dropped 13.18%, reflecting significant selling pressure across the healthcare stocks amid market volatility.
- Market Sentiment Analysis: Although oversold conditions typically signal heavy selling pressure, the potential for short-term rebounds exists if fundamentals remain intact, presenting possible buying opportunities for investors.
- Industry Outlook: With the broad pullback in healthcare stocks, market analysts suggest focusing on sector rotation opportunities, particularly in the Healthcare XLV index, which may become the next focal point for investors.
See More
Guardant Health Partners with Manulife to Launch Multi-Cancer Detection Test in Asia
- First Multi-Cancer Detection Test: Guardant Health launches the Shield™ multi-cancer detection test in Hong Kong, Singapore, and the Philippines, set to be available for eligible Manulife customers starting April 2026, marking a significant advancement in early cancer detection in the region.
- Broad Detection Range: The test screens for 10 common cancers, including bladder, colorectal, and breast cancer, using a single blood draw, specifically targeting individuals aged 45 and older at average risk, aiming to increase screening participation and reduce cancer mortality rates.
- Innovative Partnership Model: The collaboration with Manulife represents the first partnership with a major insurer in Asia, aimed at addressing unmet health needs through innovative technologies, showcasing Guardant Health's strategic commitment to advancing early cancer detection.
- Significant Market Potential: With cancer being a leading cause of death in Asia, the introduction of the Shield MCD test not only enhances customer health management awareness but also has the potential to significantly improve survival rates through early detection, driving growth for the company in the Asia-Pacific market.
See More
Survey Reveals Barriers to Colorectal Cancer Screening
- Demand for Coverage: A significant 92% of Americans aged 45 and over believe that blood-based screening should be covered with no co-pay, indicating strong public support for colorectal cancer screening that could drive policy changes to expand insurance coverage.
- Innovative Screening Tool: Guardant's Shield™ blood test has achieved a 93% adherence rate in the first 100,000 tests ordered, providing a quick and non-invasive screening option that significantly improves screening compliance and aids in early cancer detection.
- Psychological Barriers: With 71% of respondents feeling anxious before a colonoscopy and 77% stating they would be more likely to undergo screening if an FDA-approved blood test were available, psychological factors emerge as critical barriers affecting screening rates.
- Lagging Policy Updates: Although the U.S. Preventive Services Task Force has lowered the recommended screening age to 45, it has yet to update guidelines to include the new FDA-approved screening option from 2024, highlighting a disconnect between policy and innovation.
See More
Verana Health Partners with Guardant Health to Enhance Cancer Therapy Development
- Data Integration Advantage: The partnership between Verana Health and Guardant Health combines high-quality EHR data with genomic data, enabling biopharmaceutical researchers to better understand the correlations between molecular biomarkers and clinical outcomes, thereby accelerating the development of new therapies and enhancing patient care quality.
- Enhanced Clinical Insights: By integrating NMIBC EHR data with genomic data, researchers can more accurately assess patient risk and optimize treatment choices, particularly regarding the applicability of BCG therapy, which improves treatment efficacy and patient satisfaction.
- Market Coverage Expansion: This collaboration extends Verana Health's cancer care data to solid tumors such as lung, breast, and colorectal cancers, enhancing the diversity of the dataset and clinical insights, allowing it to serve 17 of the top 20 global biopharma companies.
- Regulatory Collaboration Strengthening: The combined regulatory expertise of both companies positions them as a top-tier partner for close collaboration with the FDA, further solidifying Verana Health's standing in the biopharma industry and accelerating the implementation of clinical trial solutions.
See More
Verana Health Partners with Guardant Health to Enhance Oncology Research
- Data Integration Enhances Research Efficiency: The partnership between Verana Health and Guardant Health integrates high-quality EHR data with genomic data, enabling biopharmaceutical researchers to more rapidly understand the correlations between molecular biomarkers and clinical outcomes, thereby accelerating the development of new therapies.
- Enhanced Clinical Insights: By combining NMIBC EHR data with genomic data, researchers can better select treatment options and optimize decision-making for non-muscle invasive bladder cancer patients, ultimately improving patient treatment outcomes.
- Expanded Patient Coverage: This collaboration allows Verana Health to cover over 10 million oncology patients and establishes strong ties with 17 of the top 20 global biopharma companies, enhancing its influence within the biopharma industry.
- Regulatory Collaboration Advantage: The combined regulatory expertise of both companies positions them as a top-tier partner for FDA collaborations, further driving the acceleration of clinical trial solutions and improving R&D efficiency in the life sciences sector.
See More
Guardant Reveal Expands Cancer Detection Utility in MRD Monitoring
- Tumor Classification Advances: Guardant360 Tissue demonstrates a 92% accuracy rate in identifying the likely origin of unknown primary cancers from over 6,000 tissue samples, enhancing diagnostic precision and providing new avenues for complex cancer treatment.
- Liquid Biopsy Technology Enhancement: Guardant360 Liquid achieves an actionable finding rate of 85% in metastatic breast cancer patients and 89% in advanced colorectal cancer patients, indicating its potential in clinical applications to offer personalized treatment options for more patients.
- New Cancer Detection Capability: Guardant Reveal showcases its ability to identify new primary malignancies during MRD monitoring, utilizing non-invasive liquid biopsy technology to detect new cancers over time, significantly increasing the potential for early intervention.
- Precision Treatment Opportunities: Research indicates that the tissue-based genomic instability score (GIS) can accurately detect DNA repair deficiencies in breast, ovarian, and pancreatic cancers, providing patients with opportunities for PARP inhibitor treatments, further advancing the field of precision medicine.
See More
U.S.-Iran Conflict Triggers Volatility in Healthcare Stocks
- Oversold Condition: The ongoing U.S.-Iran conflict has led to oversold conditions in the healthcare sector, with Ionis Pharmaceuticals (IONS) experiencing a 12.27% decline over the past 15 days, indicating heightened market concerns.
- Key Stock Performance: Guardant Health (GH) and Dexcom (DXCM) fell by 8.96% and 12.52%, respectively, while Humana (HUM) dropped 13.18%, reflecting significant selling pressure across the healthcare stocks amid market volatility.
- Market Sentiment Analysis: Although oversold conditions typically signal heavy selling pressure, the potential for short-term rebounds exists if fundamentals remain intact, presenting possible buying opportunities for investors.
- Industry Outlook: With the broad pullback in healthcare stocks, market analysts suggest focusing on sector rotation opportunities, particularly in the Healthcare XLV index, which may become the next focal point for investors.
See More
Guardant Health Partners with Manulife to Launch Multi-Cancer Detection Test in Asia
- First Multi-Cancer Detection Test: Guardant Health launches the Shield™ multi-cancer detection test in Hong Kong, Singapore, and the Philippines, set to be available for eligible Manulife customers starting April 2026, marking a significant advancement in early cancer detection in the region.
- Broad Detection Range: The test screens for 10 common cancers, including bladder, colorectal, and breast cancer, using a single blood draw, specifically targeting individuals aged 45 and older at average risk, aiming to increase screening participation and reduce cancer mortality rates.
- Innovative Partnership Model: The collaboration with Manulife represents the first partnership with a major insurer in Asia, aimed at addressing unmet health needs through innovative technologies, showcasing Guardant Health's strategic commitment to advancing early cancer detection.
- Significant Market Potential: With cancer being a leading cause of death in Asia, the introduction of the Shield MCD test not only enhances customer health management awareness but also has the potential to significantly improve survival rates through early detection, driving growth for the company in the Asia-Pacific market.
See More
Survey Reveals Barriers to Colorectal Cancer Screening
- Demand for Coverage: A significant 92% of Americans aged 45 and over believe that blood-based screening should be covered with no co-pay, indicating strong public support for colorectal cancer screening that could drive policy changes to expand insurance coverage.
- Innovative Screening Tool: Guardant's Shield™ blood test has achieved a 93% adherence rate in the first 100,000 tests ordered, providing a quick and non-invasive screening option that significantly improves screening compliance and aids in early cancer detection.
- Psychological Barriers: With 71% of respondents feeling anxious before a colonoscopy and 77% stating they would be more likely to undergo screening if an FDA-approved blood test were available, psychological factors emerge as critical barriers affecting screening rates.
- Lagging Policy Updates: Although the U.S. Preventive Services Task Force has lowered the recommended screening age to 45, it has yet to update guidelines to include the new FDA-approved screening option from 2024, highlighting a disconnect between policy and innovation.
See More
